Clinical Trials/NCT02902601

NCT02902601

Completed

Phase 1

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder

Janssen Research & Development, LLC0 sites70 target enrollmentOctober 17, 2016

ConditionsDepressive Disorder, Major

InterventionsJNJ-54175446, 600 mg JNJ-54175446, 150 mg Placebo

DrugsJNJ-54175446, 600 mg JNJ-54175446, 150 mg

Overview

Phase: Phase 1
Intervention: JNJ-54175446, 600 mg
Conditions: Depressive Disorder, Major
Sponsor: Janssen Research & Development, LLC
Enrollment: 70
Primary Endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).

Registry

clinicaltrials.gov

Start Date

October 17, 2016

End Date

June 7, 2017

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Janssen Research & Development, LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Body mass index (BMI) must be between 18 and 32 kilogram per square meter (kg/m\^2) inclusive
•Related to symptoms of depression: Participant must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or V diagnostic criteria for Major Depressive Disorder \[MDD\] (International Classification of Diseases (ICD)-code F32.x and F33.x), without psychotic features, as confirmed by the MINI 6.0; participant must have an IDS-C30 total score greater than or equal to (\>=) 30 using the semi-structured interview guide for the IDS-C30
•Participant is, during this episode of depression, treatment naïve OR treated with at most one Selective serotonin reuptake inhibitor (SSRI) over a minimum of 6 weeks and a maximum of 6 months, and subject is being treated at an adequate dose, showing a partial response at enrolment
•A woman of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test upon admission
•A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 3 months after receiving the last dose of study drug

Exclusion Criteria

•Has a primary DSM-IV or V diagnosis of general anxiety disorder (GAD), panic disorder, obsessive compulsive disorder, posttraumatic stress disorder, anorexia nervosa, or bulimia nervosa. Participants with comorbid GAD, social anxiety disorder, or panic disorder for whom MDD is considered the primary diagnosis are not excluded
•Has a length of current major depressive episode greater than (\>) 24 months despite adequate treatment
•Has failed more than 2 treatments with a different pharmacological mode of action despite an adequate dose and duration during a previous, or the current depressive episode
•Participant has a history of substance use disorder according to DSM-V criteria, except nicotine or caffeine, within 6 months before Screening. However, participants who have completed a treatment for (alcohol) addiction more than 8 weeks prior to first dose administration and are under continuous control of the study center, may be included if the risk to fall back is considered minimal and no significant abnormalities are shown in clinical laboratory or other predose safety assessments
•Obstructive sleep apnea/hypopnea (apnea/hypopnea index \>10) or restless legs syndrome (periodic leg movements with arousal index \>15) as assessed on the first or second polysomnography (PSG) recording during screening

Arms & Interventions

Group A: JNJ-54175446

Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.

Intervention: JNJ-54175446, 600 mg

Group A: JNJ-54175446

Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.

Intervention: JNJ-54175446, 150 mg

Group B: Placebo + JNJ-54175446

Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.

Intervention: JNJ-54175446, 600 mg

Group B: Placebo + JNJ-54175446

Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.

Intervention: JNJ-54175446, 150 mg

Group B: Placebo + JNJ-54175446

Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.

Intervention: Placebo

Group C: Placebo

Participants will receive placebo from Day 1 until Day 10.

Intervention: Placebo

Outcomes

Primary Outcomes

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Time Frame: Up to Day 17

Secondary Outcomes

Effect of JNJ-54175446 Versus Placebo on Total Sleep Deprivation (TSD)-Induced Changes in Depressive Symptoms by HDRS17/IDS-C30 Rating Scale(Baseline, Day 4 and 10: 2 to 8 hours post dose, Day 17)
Effect of JNJ-54175446 Versus Placebo on Total Sleep Deprivation (TSD)-Induced Changes in Depressive Symptoms by QIDS-SR16/QIDS-SR10 Rating Scale(Baseline, Day 3 and 10: 2 to 8 hours post dose, Day 17)
Effect of JNJ-54175446 Versus Placebo on TSD-Induced Changes in Biomarker Profiles (interleukin [IL]-1 beta, cortisol)(Day 1 and 4: Predose, 2, 8 hours postdose, Day 10: Predose)
Effect of JNJ-54175446 Versus Placebo on Latency to Persistent Sleep (LPS)(Baseline, Day 2 to 3 and Day 4 to 5)
Effect of JNJ-54175446 Versus Placebo on Total Sleep Time (TST)(Baseline, Day 2 to 3 and Day 4 to 5)
Effect of JNJ-54175446 Versus Placebo on Wake After Sleep Onset (WASO)(Baseline, Day 2 to 3 and Day 4 to 5)
Effect of JNJ-54175446 Versus Placebo on Sleep Efficiency (SE)(Baseline, Day 2 to 3 and Day 4 to 5)
Effect of JNJ-54175446 Versus Placebo on Snaith-Hamilton Pleasure Scale [SHAPS])(Baseline, Day 3, 4, 5 and 10: 2 to 8 hours postdose)
Effect of JNJ-54175446 Versus Placebo on Profile of Mood States brief form (POMS)(Baseline, Day 3, 10: 2 to 8 hours postdose, Day 4, 5: 2 to 8 and 19 hours postdose)
Effect of JNJ-54175446 Versus Placebo on Emotional Faces Recognition Test(Baseline, Day 4 and 10: 2 to 8 hours postdose)
Effect of JNJ-54175446 Versus Placebo on Soluble Biomarkers (Inclusive Ex-vivo Lipopolysaccharide [LPS]/Benzoylated(Bz) Adenosine Triphosphate [ATP]-Induced IL-1 Beta Release)(Day 1 and 4: Predose, 2, 8 hours postdose, Day 10: Predose)
Effect of JNJ-54175446 Versus Placebo on Central Pharmacodynamic (PD) by Motor Learning by Adaptive Tracking Test(Baseline, Day 10: Predose, 1, 2, 4 and 6 hour post dose)
Effect of JNJ-54175446 Versus Placebo on Sustained Attention by the Three Choice Vigilance Task (3CVT) With EEG(Baseline, Day 3, 4, 5 and 10: 2 to 8 hours postdose)
Maximum Observed Plasma Concentration (Cmax) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Minimum Observed Plasma Concentration (Cmin) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Trough Plasma Concentration (Ctrough) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Average Plasma Concentration at Steady State (Cavg) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Area Under the Plasma ConcentrationTime Curve During a Dosing Interval (tau) [AUCtau] of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Area Under the Plasma ConcentrationTime Curve From Time Zero to Time 't' (AUC[0t]) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Apparent Elimination HalfLife (t1/2) of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Ratio of the Maximum Plasma Concentration (Peak) to Trough Observed Concentration of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Accumulation Ratio Based on AUC of JNJ-54175446(Day 1: Predose, 1, 2, 4, 8, 10 hour postdose; Day 2 and 3: Predose; Day 4: Predose, 2, 4, 8 hour postdose; Day 5 and 7: Predose; Day 10: Predose, 1, 2, 4, 8, 10, 24, 48 hour postdose; Day 17)
Effect of JNJ-54175446 Versus Placebo on a Reward Test(Baseline, Day 3, 4, 5 and 10: 2 to 8 hours postdose)